A Therapy Modality Using Recombinant IL-12 Adenovirus plus E7 Protein in a Human Papillomavirus 16 E6/E7-Associated Cervical Cancer Animal Model
- 10 October 2003
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 14 (15) , 1389-1399
- https://doi.org/10.1089/104303403769211619
Abstract
Interleukin (IL)-12 has been reported to induce cellular immune responses for protection against tumor formation. Here we investigate the utility of adenoviral delivery of IL-12 as an adjuvant for a human papillomavirus E7 subunit vaccine in a mouse tumor challenge model. Direct intratumoral injection of AdIL-12 resulted in a significant suppression of tumor growth compared to the control group. Injection of E7 protein into either a tumor site or the distance site along with AdIL-12 further enhanced antitumor effects significantly higher than either AdIL-12 or E7 injection alone. This combined injection resulted in complete regression of 9-mm-sized tumor in 40% of animals as well as lasting antitumor immunity against tumor recurrence. We also evaluated immune responses induced by these injections. AdIL-12 plus E7 enhanced E7-specific antibody responses significantly higher than AdIL-12 or E7 injection. In particular, the production level of interferon (IFN)-gamma from E7-specific CD4(+) T cells was similar between AdIL-12 group and AdIL-12 + E7 group. However, IFN-gamma production from E7-specific CD8(+) T cells was the most significant when injected with AdIL-12 + E7. This was consistent with intracellular IFN-gamma staining levels of CD8(+) T cells, suggesting that AdIL-12 + E7 injection enhances antitumor immunity in the human papillomavirus (HPV) 16 tumor model through increased expansion of the cytotoxic T-lymphocyte (CTL) subset. This enhanced protection appeared to be mediated by CD8(+) T cells, as determined by in vivo T-cell subset deletion. Thus, these studies demonstrate that E7 vaccines can induce CTL responses responsible for antitumor effects in the presence of IL-12 delivered via adenovirus vectors. This likely provides one additional approach for immune therapy against cervical cancers.Keywords
This publication has 32 references indexed in Scilit:
- Differential Suppression of Human Cervical Cancer Cell Growth by Adenovirus Delivery of p53in vitro: Arrest Phase of Cell Cycle Is Dependent on Cell LineJapanese Journal of Cancer Research, 2002
- Identification of cDNA Encoding a Serine Protease Homologous to Human Complement C1r Precursor from Grafted Mouse SkinJournal of Investigative Dermatology, 2001
- Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12Cancer Gene Therapy, 1999
- Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12Cancer Gene Therapy, 1999
- CELLULAR RESPONSES TO INTERFERON-γAnnual Review of Immunology, 1997
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cellsEuropean Journal of Immunology, 1993
- The Anomalous Electrophoretic Behavior of the Human Papillomavirus Type 16 E7 Protein Is Due to the High Content of Acidic Amino Acid ResiduesBiochemical and Biophysical Research Communications, 1993
- Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.The Journal of Experimental Medicine, 1992
- Human papillomaviruses in the pathogenesis of anogenital cancerVirology, 1991